Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria vaccine + tetanus vaccine + pertussis (whole-cell) vaccine + hepatitis B vaccine
- Development stage
- Unknown
- Lead developer
- Bharat Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A tetravalent combination vaccine designed for the active immunization of infants and children against diphtheria, tetanus, pertussis (whooping cough), and hepatitis B. The vaccine contains inactivated diphtheria and tetanus toxoids, a suspension of killed *Bordetella pertussis* organisms (whole-cell pertussis), and purified recombinant hepatitis B surface antigen (HBsAg). It functions by stimulating the immune system to produce protective antibodies against the toxins produced by *Corynebacterium diphtheriae* and *Clostridium tetani*, the various antigens of the pertussis bacterium, and the surface protein of the hepatitis B virus. Typically administered as a multi-dose primary series in infancy, it provides high seroprotection rates and is a cornerstone of pediatric immunization programs in various global regions.
- Brand names
- Tritanrix-HB
- Other names
- DTPw-HBVDTPw-HepBDTPwHBdiphtheria-tetanus-pertussis (whole cell)-hepatitis B vaccine
02
Targets
HBsAg (Hepatitis B surface antigen)Diphtheria toxin
Beyond the preview
Go deeper on diphtheria vaccine + tetanus vaccine + pertussis (whole-cell) vaccine + hepatitis B vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria vaccine + tetanus vaccine + pertussis (whole-cell) vaccine + hepatitis B vaccine.